Evaluation of the efficacy and safety of immunotherapy in sarcoma: a two-center study

• DOI: 10.3389/fimmu.2024.1292325
• Publication Date: 2024-03-22T04:31:18Z
• Authors: Zhichao Liao; Jianjin Teng; Tao Li; Haotian Liu; Ting Li; Chao Zhang; Ruwei Xing; Sheng Teng; Yun Yang; Jun Zhao; Wanyi Xiao; Gengpu Zhang; Mulin Jun Li; Weitao Yao; Jilong Yang
• Keywords: Single Center; Combination therapy

Background Sarcoma is a highly heterogeneous malignancy with poor prognosis. Although chemotherapy and targeted therapy have improved the prognosis to some extent, efficacy remains unsatisfactory in patients. The safety of immunotherapy sarcoma need further evaluation. Methods We conducted two-center study patients receiving PD-1 at Tianjin Medical University Cancer Institute Hospital Henan Provincial Hospital. treatment regimens included inhibitor monotherapy combination based on inhibitors. observed primary endpoints were median progression-free survival (mPFS) overall (mOS). Survival curves compared using Kaplan−Meier method. Results A total 43 from two centers. follow-up time for all was 13 months (range, 1-48 months). In group 37 advanced or unresectable sarcoma, mPFS 6 (95%CI: 5-12 months), mOS 16 10-28 ORR 10.8% (4/37), DCR 18.9% (7/37). Subgroup analysis showed no significant differences (p=0.11) (p=0.88) between PD-L1 negative/positive expression. There also (p=0.13) (p=0.72) therapy. Additionally, there (p=0.52) (p=0.49) osteogenic soft tissue sarcoma. Furthermore, results (p=0.66) (p=0.96) inhibitors combined AI chemotherapy. Among adjuvant after surgery, 15 6-NA not reached. terms safety, most adverse events mild (grade 1-2) manageable. severe grade 4 bone marrow suppression, which occurred but resolved treatment. one case event related hypertension. Conclusion Immunotherapy an effective modality manageable safety. Further inclusion more prospective clinical trials needed validate these findings.